Opinion
Video
Author(s):
Stephen Freedland, MD, reviews findings from the EMBARK study, which investigated enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer.
Data reinforce isodose MHFRT as standard of care radiotherapy regimen
Dr. Murphy on increasing diversity in cancer clinical trials
Trial launches of CBP/p300 inhibitor in mCRPC
Dr. Schwen on focal therapies for prostate cancer
Michael R. Folkert, MD, PhD, discusses real-world outcomes with spacer in prostate cancer
Radioligand therapy shows promising safety in patients with mCRPC